Sponsored by
Delytact is an oncolytic herpes simplex virus that in a small trial showed amazing results in recurrent glioblastoma. Japan conditionally approved it and the treatment is now available only in Japan. We have been trying to get access here in the USA but it most likely won't happen for a while. It is an embarrassment that Japan and France (See our recent article on Onc-201 being approved in France) are so far ahead of the USA in giving approvals to drugs for serious diseases. We in the USA can not get access to the most promising treatments. We are trying to fix that. Go to https://virtualtrials.org/activism.cfm#/1/ for details on our proposed law to fix this!